Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Immunology

• Publication date

  2006-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.176.12.7308PMID 16751374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Directed evolution of human T-cell receptors with picomolar affinities by phage display

  2005cited by this paper
• In Vitro and In Vivo Characterization of a Novel Antibody-Like Single-Chain TCR Human IgG1 Fusion Protein1

  2005cited by this paper
• NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

  2005cited by this paper
• Structural and kinetic basis for heightened immunogenicity of T cell vaccines

  2005cited by this paper
• Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition*

  2005cited by this paper
• Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1

  2005cited by this paper
• T cell killing does not require the formation of a stable mature immunological synapse

  2004cited by this paper
• Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity

  2004cited by this paper
• Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1

  2004cited by this paper
• Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response1

  2004cited by this paper
• Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments

  2004cited by this paper
• A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

  2004cited by this paper
• HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.

  2004cited by this paper
• TCRs with high affinity for foreign pMHC show self-reactivity

  2003cited by this paper
• Making sense of mass destruction: quantitating MHC class I antigen presentation

  2003cited by this paper
• Stable, soluble T-cell receptor molecules for crystallization and therapeutics.

  2003cited by this paper
• Recombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactions

  2003cited by this paper
• CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

  2002cited by this paper
• Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity

  2002cited by this paper
• Direct observation of ligand recognition by T cells

  2002cited by this paper
• Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

  2002cited by this paper
• A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells

  2002cited by this paper
• Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

  2002cited by this paper
• Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution

  2001cited by this paper
• A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.

  2001cited by this paper
• A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway.

  2001cited by this paper
• Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

  2000cited by this paper
• Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach

  2000cited by this paper
• Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

  2000cited by this paper
• Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1

  2000cited by this paper
• A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains

  2000cited by this paper
• In vitro evolution of a T cell receptor with high affinity for peptide/MHC.

  2000cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures.

  1999cited by this paper
• Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3

  1999cited by this paper
• Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.

  1998cited by this paper
• Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

  1998cited by this paper
• LAGE‐1, a new gene with tumor specificity

  1998cited by this paper
• A naturally processed peptide presented by HLA-A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity.

  1997cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper
• Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion

  1996cited by this paper
• Ubiquitin‐assisted dissection of protein transport across membranes.

  1994cited by this paper
• Identification of self peptides bound to purified HLA-B27

  1991cited by this paper
• In vivo half-life of a protein is a function of its amino-terminal residue.

  1986cited by this paper

• Avidity-optimized TCR-T cells target KRAS neoantigens for potent cancer clearance and tumor microenvironment remodeling

  2026cites this paper
• Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.

  2026cites this paper
• Targeting peptide-HLA complexes for precision immunotherapy.

  2026cites this paper
• T-cell signaling relies on partial CD45-exclusion at sub-micron sized cellular contacts

  2025cites this paper
• T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy

  2024cites this paper
• Fast on-rates of chimeric antigen receptors enhance the sensitivity to peptide MHC via antigen rebinding

  2024cites this paper
• First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

  2024cites this paper
• Co-STARs combine the advantages of chimeric antigen and T-cell receptors for the treatment of tumors with low antigen densities

  2024cites this paper
• Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation

  2024cites this paper
• The landscape of T cell antigens for cancer immunotherapy

  2023cites this paper
• T cell receptor binding affinity governs the functional profile of cancer-specific CD8 + T cells

  2023cites this paper
• Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.

  2023cites this paper
• Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.

  2023cites this paper
• Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting.

  2023cites this paper
• Immunotherapy for Meningiomas.

  2023cites this paper
• ABBV-184: A novel survivin-specific TCR/CD3 bispecific T cell engager is active against both solid tumor and hematological malignancies.

  2023cites this paper
• Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy

  2022cites this paper
• Therapeutic bispecific antibodies against intracellular tumor antigens.

  2022cites this paper
• Immune mobilising T cell receptors redirect polyclonal CD8+ T cells in chronic HIV infection to form immunological synapses

  2022cites this paper
• Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.

  2022cites this paper
• A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.

  2022cites this paper
• Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells

  2022cites this paper
• Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers

  2021cites this paper
• DNA origami patterning of synthetic T cell receptors reveals spatial control of the sensitivity and kinetics of signal activation

  2021cites this paper
• Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β

  2021cites this paper
• Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.

  2020cites this paper
• Identification of Antigenic Targets.

  2020cites this paper
• Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells

  2020cites this paper
• Cell Activation and Signaling in Lymphocytes

  2020cites this paper
• The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses

  2020cites this paper
• Engineered T cells directed at tumors with defined allelic loss.

  2020cites this paper
• Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo

  2020cites this paper
• CRISPR-mediated deletion of the Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) improves human T cell function for adoptive T cell therapy

  2020cites this paper
• Intracellular targets as source for cleaner targets for the treatment of solid tumors.

  2019cites this paper
• Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses

  2019cites this paper
• Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.

  2019cites this paper
• Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer

  2019cites this paper
• Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours.

  2019cites this paper
• Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy

  2019cites this paper
• Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

  2019cites this paper
• Molecular mechanisms of T cell sensitivity to antigen

  2018cites this paper
• Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology

  2018cites this paper
• An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

  2018cites this paper
• Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

  2017cites this paper
• TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets

  2017cites this paper
• Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors

  2016cites this paper
• Antigen Selection for Enhanced Affinity T-Cell Receptor–Based Cancer Therapies

  2016cites this paper
• T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma

  2016cites this paper
• Human leucocyte antigen class I‐redirected anti‐tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells

  2016cites this paper
• Molecular Immunology

  2015cites this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cites this paper
• Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing

  2015cites this paper
• ImmTACs for targeted cancer therapy: Why, what, how, and which.

  2015cites this paper
• T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells

  2015cites this paper
• Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

  2015cites this paper
• Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies

  2014cites this paper
• The link between CD8+ T-cell antigen-sensitivity and HIV-suppressive capacity depends on HLA restriction, target epitope and viral isolate

  2014cites this paper
• Specific Targeting of a Naturally Presented Osteosarcoma Antigen, Papillomavirus Binding Factor Peptide, Using an Artificial Monoclonal Antibody*

  2014influential citation
• ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells

  2014cites this paper
• Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2

  2014cites this paper
• Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide–MHC Interactions

  2014cites this paper
• From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

  2014cites this paper
• Modified Effector CD8 - Antigen Receptor Chimeric ζ CD20-CD28-CD3 - of AntiAntigen Density Governs the Efficacy

  2014cites this paper
• Phenotypic models of T cell activation

  2014cites this paper
• Soluble T‐Cell Antigen Receptors

  2013cites this paper
• Redirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics

  2013cites this paper
• Molecular engineering of high affinity T-cell receptors for bispecific therapeutics

  2013cites this paper
• ImmTACs

  2013cites this paper
• Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells

  2013cites this paper
• High‐Affinity Monoclonal T‐Cell Receptor (mTCR) Fusions

  2013cites this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cites this paper
• Defining Multiple Myeloma as a Target for DNA Vaccines

  2013cites this paper
• CLINICAL Cardiovascular toxicity and titin cross-reactivity of af fi nity-enhanced T cells in myeloma and melanoma

  2013cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• ImmTACs: Novel bi-specific agents for targeted cancer therapy.

  2013cites this paper
• Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

  2012cites this paper
• Monoclonal TCR-redirected tumor cell killing

  2012cites this paper
• Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

  2012cites this paper
• T cell receptor engineering.

  2012cites this paper
• Diversity‐oriented approaches for interrogating T‐cell receptor repertoire, ligand recognition, and function

  2012cites this paper
• Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.

  2011cites this paper
• T-cell receptor gene therapy: critical parameters for clinical success.

  2011cites this paper
• NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses

  2010cites this paper
• Coreceptor TCR and by the Use of the CD 8 Cells Is Modulated by the Affinity of Reticulum of NY-ESO-1 Specific T Release from the Endoplasmic 2 + Ca

  2010cites this paper
• Ca2+ Release from the Endoplasmic Reticulum of NY-ESO-1–Specific T Cells Is Modulated by the Affinity of TCR and by the Use of the CD8 Coreceptor

  2010cites this paper
• Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells?

  2009cites this paper
• Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

  2009cites this paper
• Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

  2009cites this paper
• Mechanisms and functions for the duration of intercellular contacts made by lymphocytes

  2009cites this paper
• Engineering Of Therapeutic Proteins

  2009cites this paper
• This information is current as Cell Functions TCR CDRs Can Enhance Antigen-Specific T Single and Dual Amino Acid Substitutions in and

  2008cites this paper
• Antigens for cancer immunotherapy.

  2008cites this paper
• About human tumor antigens to be used in immunotherapy.

  2008cites this paper
• Lentivector immunization induces tumor antigen‐specific B and T cell responses in vivo

  2008cites this paper
• Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

  2008cites this paper
• Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

  2007cites this paper
• Display, engineering, and applications of antigen-specific T cell receptors.

  2007cites this paper
• The HLA A*0201–restricted hTERT540–548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor

  2007cites this paper
• The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation

  2007cites this paper
• Lines Ability to Recognize and Kill Tumor Cell T Cells with the + Display Provide CD 4 High-Affinity TCRs Generated by Phage Rosenberg and

  2007cites this paper